Research Paper Volume 16, Issue 1 pp 779—798
SPC25 as a novel therapeutic and prognostic biomarker and its association with glycolysis, ferroptosis and ceRNA in lung adenocarcinoma
Figure 1. SPC25 expression levels in cancers and prognostic value in LUAD, as well as association with clinicopathological characteristics for LUAD patients. (A) SPC25 levels in different tumor tissues and paracancerous tissues based on the TIMER database. (B–D) SPC25 levels in LUAD samples and normal samples in the (B) GSE31210, (C) GSE116959 and (D) GSE7670. (E, F) Prognostic analysis of SPC25 expression on OS (E) and DFS (F) in LUAD based on the GEPIA database (log-rank test). (G) SPC25 expression was explored in different pathological stages based on the TCGA LUAD database. (H) SPC25 expression was explored in different pathological T stages based on the TCGA LUAD database. (I) SPC25 expression was explored in different pathological N stages based on the TCGA LUAD database. (J) SPC25 expression was explored in different pathological M stages based on the TCGA LUAD database. Abbreviations: TCGA: the Cancer Genome Atlas; LUAD: lung adenocarcinoma; OS: overall survival; DFS: disease free survival. (***p < 0.001; **p < 0.01; *p < 0.05; Abbreviation: ns: not significant).